Clinical Trial Update: Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study [Phase 2]

View source ↗

Summary

Phase 2 open-label safety extension trial of a gastric-retentive formulation of carbidopa/levodopa for Parkinson's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Gastric Retentive Carbidopa/Levodopa (carbidopa/levodopa)

Snippet

Sponsor: Intec Pharma Ltd. | Conditions: Parkinson's Disease | Phase 2 | Status: WITHDRAWN